News

HRT cancer risk persists for three years

05-Mar-08

Women who have stopped taking oestrogen plus progesterone hormone replacement therapy (HRT) could still be at an increased risk of developing cancer three years later, US research suggests.
In 2002, the Women's Health Initiative (WHI) study was terminated early after oestrogen plus progesterone HRT was found to be linked to a 26 per cent increased risk of breast cancer and a 29 per cent higher risk of heart attack. 

Subsequently, women have been advised to take HRT for as short a time as possible. But follow-up data from the WHI suggests that the increased cancer risk remains even after stopping HRT. 

The latest data comes from follow-up of 15,730 postmenopausal women, aged 50-79, who had participated in the WHI study.

Half the women had been taking oestrogen plus progesterone HRT, but stopped the treatment in 2002 when the WHI study was abandoned. The rest of the women had taken placebo. 

Follow-up from July 2002 until March 2005, revealed that 281 women who had received HRT went on to develop cancer, compared with 218 who had not received HRT.

Overall, the combined risk of suffering heart disease, stroke, hip fracture or cancer increased by 12 per cent in the HRT group, compared with the placebo group. 

Researchers from the University of North Carolina hope the findings can help calculate optional use of HRT.

sanjay.tanday@haymarket.com

JAMA 2008; 299:1036-45

Comment below and tell us what you think 

Comments

Only registered users may comment. Log in now or register for a free account.

Login to comment


forgotten your password?

Quick search - use * for an abbreviated search, eg nico*

 
 

Healthcare Republic Forums

 

Quick search - use * for an abbreviated search, eg nico*

 
 

Latest Clinical Articles

Clinical Review - Renal colic

Contributed by Mr Ranan DasGupta, specialist registrar and Mr Jonathon Olsburgh, consultant urologic... Read more

Clinical Review - Stroke

By Dr Helen Hosker, GP and clinical commissioning lead for stroke, NHS Manchester, and Dr Pippa Tyrr... Read more

Sjogren's syndrome

Although it is one of the most common autoimmune diseases, Sjogren's syndrome remains underdiagnosed... Read more

Show all clinical articles

MIMS Product News

New drug - Intelence

Janssen-Cilag has launched Intelence (etravirine) for the treatment of HIV infection in antiretrovir... Read more

New drug - Doribax

Janssen-Cilag has launched Doribax (doripenem) for the treatment of nosocomial pneumonia (including ... Read more

Ebixa dosing made easier

Ebixa (memantine) is now licensed for once-daily administration in the treatment of patients with mo... Read more

Jobs